Universal Health Realty Income Trust
UHT- Exchange
- NYSE
- Industry
- Real Estate Investment Trusts
- SEC CIK
- 0000798783
No open-market purchases or sales by Universal Health Realty Income Trust insiders were filed in the last 90 days; 176 institutions reported holding it in 13F filings for Q3 2026, worth $321.3M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 10:32 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net income for FY2025: $17.6M (17.8% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 25, 2026 | Feb 26, 2025 | Feb 27, 2024 | Feb 27, 2023 | Feb 24, 2022 |
| Revenue | $99.2M | $99.0M | $95.6M | $90.6M | $84.2M |
| Operating income | $34.8M | $36.8M | $31.3M | $30.7M | $28.9M |
| Net income | $17.6M | $19.2M | $15.4M | $21.1M | $109.2M |
| EPS, basic | $1.27 | $1.39 | $1.12 | $1.53 | $7.94 |
| EPS, diluted | $1.27 | $1.39 | $1.11 | $1.53 | $7.92 |
| Weighted shares, basic | 13.8M | 13.8M | 13.8M | 13.8M | 13.8M |
| Weighted shares, diluted | 13.9M | 13.8M | 13.8M | 13.8M | 13.8M |
| Margins and growth | |||||
| Operating margin | 35.0% | 37.2% | 32.8% | 33.8% | 34.3% |
| Net margin | 17.8% | 19.4% | 16.1% | 23.3% | 129.7% |
| Revenue growth, year over year | +0.2% | +3.6% | +5.5% | +7.6% | +7.9% |
| Net income growth, year over year | −8.4% | +24.9% | −27.0% | −80.7% | +461.4% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 25, 2026 | Feb 26, 2025 | Feb 27, 2024 | Feb 27, 2023 | Feb 24, 2022 |
| Cash and equivalents | $6.69M | $7.10M | $8.21M | $7.61M | $22.5M |
| Intangible assets | $5.64M | $7.33M | $9.11M | $9.45M | $9.97M |
| Total assets | $564.9M | $580.9M | $596.4M | $607.5M | $598.4M |
| Long-term debt | $374.8M | $368.4M | $359.7M | $343.1M | $329.1M |
| Total liabilities | $412.5M | $401.3M | $395.4M | $378.4M | $363.1M |
| Shareholders' equity | $152.4M | $179.5M | $200.9M | $229.1M | $235.3M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 25, 2026 | Feb 26, 2025 | Feb 27, 2024 | Feb 27, 2023 | Feb 24, 2022 |
| Operating cash flow | $49.1M | $46.9M | $42.9M | $46.8M | $47.7M |
| Capital expenditures | – | – | $7.62M | $13.6M | $13.0M |
| Free cash flow | – | – | $35.3M | $33.2M | $34.7M |
| Depreciation and amortization | $28.9M | $27.4M | $27.7M | $26.6M | $27.5M |
| Stock-based compensation | $936.0K | $853.0K | $780.0K | $780.0K | $947.0K |
| Dividends paid | $41.0M | $40.4M | $39.8M | $39.2M | $38.5M |
| Investing cash flow | -$15.0M | -$13.9M | -$19.1M | -$36.7M | -$24.4M |
| Financing cash flow | -$34.5M | -$34.1M | -$23.2M | -$25.0M | -$6.54M |
| Net change in cash | -$411.0K | -$1.11M | $598.0K | -$14.9M | $16.8M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 0.9% | 0.9% | 0.8% | 0.9% | 1.1% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 31, 2026 | 13.9M | +0.2% | SEC |
| Jul 31, 2026 | 13.9M | +0.2% | SEC |
| Apr 30, 2026 | 13.9M | +0.2% | SEC |
| Jan 31, 2026 | 13.9M | +0.2% | SEC |
| Oct 31, 2025 | 13.9M | +0.2% | SEC |
| Jul 31, 2025 | 13.9M | +0.2% | SEC |
| Apr 30, 2025 | 13.9M | +0.2% | SEC |
| Jan 31, 2025 | 13.9M | +0.2% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.